Editorial: Germline variants within RET: Clinical utility or scientific playtoy?

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 11, 2005, Pages 6334-6336

  Weber, Frank ^a,b   Eng, Charis ^a,c,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET;

EDITORIAL; ENDOCRINE TUMOR; GENE MUTATION; GENETIC TRANSCRIPTION; GENOMICS; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN GENOME PROJECT; MISSENSE MUTATION; NEUROFIBROMATOSIS; NONHUMAN; PARATHYROID HYPERPLASIA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; SIPPLE SYNDROME; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA;

CALCITONIN; CARCINOMA, MEDULLARY; GERM-LINE MUTATION; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; THYROID NEOPLASMS;

EID: 27744515971     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2030     Document Type: Editorial

References (18)

1. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579
2. Eng C 1999 RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380-393
3. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ 1994 Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 3:2163-2167
4. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fekete C, Ponder BA, Munnich A 1994 Mutations of the RET protooncogene in Hirschsprung's disease. Nature 367:378-380
5. Cosma MP, Cardone M, Carlomagno F, Colantuoni V 1998 Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Mol Cell Biol 18:3321-3329
6. Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M 1996 Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO J 15:2717-2725
7. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhäusl W, Vierhapper H 2005 Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90:6232-6236
8. Borrego S, Wright FA, Fernandez RM, Williams N, Lopez-Alonso M, Davuluri R, Antinolo G, Eng C 2003 A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet 72:88-100
9. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S 2001 Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol (Oxf) 55:399-402
10. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C 1999 Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 18:1369-1373
11. Agrawal S, Pilarski R, Eng C 2005 Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Hum Mol Genet 14:2459-2468
12. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, AntinoloG1998 Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 83:3361-3364
13. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C 1999 Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771-774
14. Borrego S, Ruiz A, Saez ME, Gimm O, Gao X, Lopez-Alonso M, Hernandez A, Wright FA, Antinolo G, Eng C 2000 RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. J Med Genet 37:572-578
15. Wiench M, Wygoda Z, Gubala E, Wloch J, Oczko M, Jarzab B 2001 The genetic background of medullary thyroid carcinoma in young patients. Folia Histochem Cytobiol 39(Suppl 2):163-164
16. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, Barale R, Pacini F, Pinchera A 2004 RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 89:3579-3584
17. Gath R, Goessling A, Keller KM, Koletzko S, Coerdt W, Muntefering H, Wirth S, Hofstra RM, Mulligan L, Eng C, von Deimling A 2001 Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease. Gut 48:671-675
18. Fitze G, Schierz M, Kuhlisch E, Schreiber M, Ziegler A, Roesner D, Schackert HK 2003 Novel intronic polymorphisms in the RET proto-oncogene and their association with Hirschsprung disease. Hum Mutat 22:177